News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

23.05.2019 | Curetis GmbH

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced key data from its succe...

21.05.2019 | Curetis GmbH

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Curetis will recei...

17.05.2019 | Curetis GmbH

Curetis Announces Financial Results for the First Three Months of 2019

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first threemonths ended March31, 2019,and provided a business update f...

15.05.2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first dosing of its lead drug ...

09.04.2019 | immatics biotechnologies GmbH

Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T...

04.04.2019

Retina Implant AG discontinues business activities

Unfortunately, the history of our company is coming to an end. The shareholders of Retina Implant AG resolved to dissolve the company at an extraordinary general meeting held on 19 March 2019.

02.04.2019 | Curetis GmbH

Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNATesting for Antibiotic Resistance

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it will introd...

26.03.2019 | Curetis GmbH

Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has entered...

20.03.2019 | Mireca Medicines GmbH

Mireca’s key patent application receives “Notice of Allowance” from USPTO

Tübingen, Germany, February 20th, 2019 – Mireca Medicines GmbH, an ophthalmology start-up company developing treatments for inherited retinal degeneration, receives the validating “Notice of Allowance” from the USPTO for its proprietary formulation a...

19.03.2019

Idris Oncology one of first companies to receive free human tissue through Codex4SME’s

The Leiden based biotechnology firm Idris Oncology is one of the three SME’s in Europe to receive human tissue through the Codex4SME’s consortium, in order to help them p...

27.02.2019

CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases

12.02.2019 | Eberhard Karls Universität Tübingen

How sleep strengthens the immune system

Scientists at the University of Tübingen discover new mechanism that supports our immune system during sleep

04.02.2019 | CureVac AG

CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical

Drug development veteran to focus on advancing the company’s preclinical portfolio of programs in naturally optimized mRNA

01.02.2019 | Eberhard Karls Universität Tübingen

Novel unusual sugar from cyanobacteria acts as natural herbicide

Chemists and microbiologists at Tübingen University discover sugar molecule that inhibits the growth of plants and microorganisms and is harmless to human cells ‒ An alternative to controversial glyphosate?

28.01.2019 | Eberhard Karls Universität Tübingen

A safer way to correct faulty DNA

University of Tübingen researchers take RNA editing a step closer to treating hereditary diseases

28.01.2019

CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer

Drug development veteran to lead CureVac’s global product development efforts as the company looks to advance its pipeline of mRNA-based products

21.01.2019 | Fraunhofer-Institut für Produktionstechnik und Automatisierung IPA

From Stuttgart to the world: Fraunhofer IPA turns 60

"Future is our product" is the motto of the Fraunhofer Institute for Manufacturing Engineering and Automation IPA. The institute produces innovations and solutions for industrial applications and bridges the gap between science and practice. This is ...

08.01.2019 | CureVac AG